BioMarin Pharmaceutical — May 4, 2026 release

BioMarin will continue to include interest expense related to the Amicus financing in both GAAP and Non‑GAAP financial results. Guidance is subject to change based on various factors including finalization of purchase accounting. • The company expects approximately two-thirds of 2026 Non-GAAP Diluted EPS to be recognized in the second half of 2026, primarily due to the anticipated timing of revenue (more than 55% of 2026 Total Revenues is expected in 2H). Non-GAAP Diluted EPS in Q2 is expected to be modestly higher than in Q1. Item Provided on February 23, 2026 Updated May 4, 2026 Total Revenues $3,325 to $3,425 $3,825 to $3,925 Enzyme Therapies $2,225 to $2,275 $2,725 to $2,775 VOXZOGO $975 to $1,025 Unchanged Other Revenues (1) $100 to $125 Unchanged Non-GAAP Diluted EPS (2)(3)(4) $4.95 to $5.15 $4.85 to $5.05 (1)    Other Revenues includes KUVAN, ROCTAVIAN, and royalties. (2) Refer to Non-GAAP Information beginning on page 9 of this press release for definition of Non-GAAP Diluted EPS. (3)    Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. (4) Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%, which is subject to change as the company completes its integration activities and purchase accounting. BioMarin will host a conference call and webcast to discuss first quarter 2026 financial results today, Monday, May 4, 2026, at 4:30 p.m. ET. This event can be accessed throu